Volume 32, Number 5—May 2026
CME ACTIVITY - Research
Frequency and Duration of Diagnostic Delays Associated with Coccidioidomycosis and Risk Factors for Missed Diagnoses, United States
Desmond D. Barber, Alan T. Arakkal, George R. Thompson, John W. Baddley, Joe E. Cavanaugh, Aaron C. Miller, and Philip M. Polgreen
Table 4
Results of exploratory logistic regression model in study of frequency and duration of diagnostic delays associated with coccidioidomycosis and risk factors for missed diagnoses, United States*
| Potential risk factor | Odds ratio (95% CI) |
|---|---|
| Database source | |
| Commercial | Referent |
| Medicare | 0.61 (0.47–0.78) |
| Medicaid |
0.61 (0.48–0.77) |
| Age group, y | |
| <18 | Referent |
| 18–34 | 0.89 (0.77–1.00) |
| 35–44 | 0.94 (0.82–1.08) |
| 45–54 | 0.94 (0.81–1.06) |
| 55–64 | 0.93 (0.82–1.05) |
| >65 |
1.48 (1.15–1.98) |
| Female sex |
0.99 (0.93–1.05) |
| Rural location |
1.27 (1.04–1.60) |
| Asthma diagnosis before delay window | 1.34 (1.18–1.49) |
| COPD diagnosis before delay window | 1.56 (1.36–1.80) |
| Chest CT before delay window | 1.42 (1.26–1.61) |
| Chest radiography before delay window |
1.21 (1.12–1.30) |
| Respiratory antibiotic prescriptions filled during delay window | 3.42 (3.18–3.69) |
| Inhaler prescriptions filled during delay window | 2.64 (2.34–2.99) |
*Odds ratios corresponding to the odds of a patient experiencing a diagnostic delay are aggregated across bootstrap trials. The mean odds ratio along with 95% CI are reported across trials for each potential risk factor. See Appendix Table 3 for effects associated with month and year. COPD, chronic obstructive pulmonary disorder; CT, computed tomography.
Page created: March 23, 2026
Page updated: May 11, 2026
Page reviewed: May 11, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.